Patents by Inventor Chunhong He

Chunhong He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors
    Publication number: 20200317680
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Imidazotriaines and imidazopyrimidines as kinase inhibitors
    Patent number: 10738052
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 11, 2020
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS
    Publication number: 20200247811
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Application
    Filed: October 4, 2019
    Publication date: August 6, 2020
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10717737
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 21, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Wenqing Yao, Fenglei Zhang
  • IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20200199131
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS
    Publication number: 20200181151
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: November 15, 2019
    Publication date: June 11, 2020
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20200181077
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 20, 2019
    Publication date: June 11, 2020
    Applicant: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • Imidazopyridines and imidazopyrazines as LSD1 inhibitors
    Patent number: 10640503
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 5, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20200131185
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: September 4, 2019
    Publication date: April 30, 2020
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20200095244
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 26, 2020
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
  • Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
    Patent number: 10556908
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • Pyrrolopyrimidine derivatives as TAM inhibitors
    Patent number: 10519163
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10513493
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: December 24, 2019
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
    Patent number: 10472367
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 12, 2019
    Assignees: INCYTE INCORPORATION, INCYTE HOLDINGS CORPORATION
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS
    Publication number: 20190337957
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: April 8, 2019
    Publication date: November 7, 2019
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Chunhong He, Taisheng Huang
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10450313
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: October 22, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Liang Lu, Wenqing Yao, Chunhong He, Fenglei Zhang
  • Pyrrolotriazine compounds as TAM inhibitors
    Patent number: 10442810
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 15, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3
    Publication number: 20190240220
    Abstract: The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: January 2, 2019
    Publication date: August 8, 2019
    Inventors: Wenqing Yao, Colin Zhang, Meizhong Xu, Jincong Zhuo, Chunhong He
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20190225601
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: April 2, 2019
    Publication date: July 25, 2019
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20190211014
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 19, 2018
    Publication date: July 11, 2019
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang